Truace
Subscribe

AI is moving into drug regulation, but this review gives no measured results

Study title: Artificial Intelligence in Pharmaceutical Regulatory Science: Opportunities, Challenges, and Emerging Frameworks

Digital transformation in pharmaceutical regulatory affairs is accelerating as global submissions grow in complexity and traditional document-based workflows reach their limits. Artificial intelligence (AI), particularly natural language processing (NLP), is increasingly being explored to support regulatory data management, document preparation, and decision support activities.

Read the study abstract

Digital transformation in pharmaceutical regulatory affairs is accelerating as global submissions grow in complexity and traditional document-based workflows reach their limits. Artificial intelligence (AI), particularly natural language processing (NLP), is increasingly being explored to support regulatory data management, document preparation, and decision support activities. This review examines AI adoption across pharmaceutical regulatory science, including initiatives from major regulatory agencies, AI-supp…

By the Truvace desk1 min read1 sourceEvidence: Emerging · 30/100 — Commentary, opinion, or narrative review · 1 independent sourcePeer-reviewedTRV-2026-1151· cite & verify
Artificial Intelligence in Pharmaceutical Regulatory Science: Opportunities, Challenges, and Emerging Frameworks
Insurance policy issued by the Post Office of the Japanese Government-General of Korea (January 1936) by The Government-General of Korea, Empire of Japan.. Public domain

In brief

This review examines AI adoption across pharmaceutical regulatory science, including initiatives from major regulatory agencies, AI-supported regulatory workflows, and emerging governance and interoperability frameworks. The review further examines emerging regulatory data ecosystems and governance frameworks that may support the responsible integration of AI into regulatory processes.

Main points

  1. Digital transformation in pharmaceutical regulatory affairs is accelerating as global submissions grow in complexity and traditional document-based workflows reach their limits.
  2. Artificial intelligence (AI), particularly natural language processing (NLP), is increasingly being explored to support regulatory data management, document preparation, and decision support activities.
  3. This review examines AI adoption across pharmaceutical regulatory science, including initiatives from major regulatory agencies, AI-supported regulatory workflows, and emerging governance and interoperability frameworks.

The problem

Robust evidence of sustained improvements in regulatory performance and long-term impact from AI in pharmaceutical regulation remains limited.

The rundown

Digital transformation in pharmaceutical regulatory affairs is accelerating as global submissions grow in complexity and traditional document-based workflows reach their limits. Artificial intelligence (AI), particularly natural language processing (NLP), is increasingly being explored to support regulatory data management, document preparation, and decision support activities.

This review examines AI adoption across pharmaceutical regulatory science, including initiatives from major regulatory agencies, AI-supported regulatory workflows, and emerging governance and interoperability frameworks. Current applications include document classification, data extraction, Common Technical Document (CTD) support, pharmacovigilance, and predictive analytics.

Sources

  1. Peer-reviewedThe AAPS Journal2026-09-18

The debate